Fulgent Shares Preliminary Data from Poster Presentation at ESMO 2025 Conference

Core Insights - Fulgent Genetics, Inc. announced preliminary clinical data from its ongoing phase 2 clinical trial for FID-007 in combination with cetuximab for the second-line treatment of recurrent or metastatic head and neck cancer [1] Group 1: Company Overview - Fulgent Genetics is a technology-based company with established businesses in clinical diagnostics and therapeutic development [1] Group 2: Clinical Trial Information - The preliminary data cutoff for the ongoing phase 2 clinical trial was September 25, 2025 [1]